Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 5/20 | 0.37 |
| ▸ | CCR5 | P51681 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | TACR1 | P25103 | 2/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4106183 | 0.93 | CCR5 (0.38) | CCR5CYP2D6PPARGRORCPPARA | |
| SCHEMBL1096628 | 0.93 | CASR (0.39) | CASRCCR5CYP2D6PPARGPPARA | |
| SCHEMBL1096965 | 0.93 | CASR (0.39) | CASRCCR5CYP2D6TACR1 | |
| SCHEMBL4096448 | 0.90 | CCR5 (0.41) | CASRCCR5CYP2D6 | |
| SCHEMBL4106153 | 0.90 | CCR5 (0.39) | CASRCCR5CYP2D6 | |
| SCHEMBL4100556 | 0.88 | CCR5 (0.39) | CASRCCR5PPARGRORCPPARA | |
| SCHEMBL4110113 | 0.88 | CCR5 (0.41) | CASRCCR5RORCTACR1 | |
| SCHEMBL1096703 | 0.87 | CCR5 (0.39) | CASRCCR5PPARGPPARATACR1 | |
| SCHEMBL1095299 | 0.87 | CCR5 (0.38) | CASRCCR5CYP2D6TACR1 | |
| SCHEMBL1096793 | 0.87 | CCR5 (0.37) | CASRCCR5TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1882684-B1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-7585886-B2 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARAMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1882684-A1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | CASR, CYP2R1, PTH1R | CASR 1/4885CCR5 1050/4885CYP2D6 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.